This new paradigm of personalized medicine will break the cycle of “trial and error” medicine and link the test to patient-tailored action and evidence-based therapy and treatment plans. Multiple gene testing will be more cost-effective in terms of changing therapy regimens, stratifying responders vs. non-responders to drugs, etc.

The use of genomic markers for the assessment of chemosensitivity and chemoresistance may dramatically improve response rates to chemotherapy among patients, along with having a huge impact on the risk-benefit ratio for these patients.

The use of genomic markers to guide targeted therapy selection enables clinicians to match patients with the most effective treatments, minimising unnecessary toxicity and improving overall outcomes across a wide range of cancers.

This new paradigm of personalized medicine will break the cycle of “trial and error” medicine and link the test to patient-tailored action and evidence-based therapy and treatment plans. Multiple gene testing will be more cost-effective in terms of changing therapy regimens, stratifying responders vs. non-responders to drugs, etc.

The use of genomic markers for the assessment of chemosensitivity and chemoresistance may dramatically improve response rates to chemotherapy among patients, along with having a huge impact on the risk-benefit ratio for these patients.

The use of genomic markers to guide targeted therapy selection enables clinicians to match patients with the most effective treatments, minimising unnecessary toxicity and improving overall outcomes across a wide range of cancers.